Answers are grounded in this paper and cite their sources.
Shows B28 treatment decreases amyloid plaques in APP knock-in mice, indicating therapeutic potential.
knock-in mice, weekly infusions of B28 for four months markedly reduced both amyloid plaques and Aβ oligomers, attenuated plaque-associated astrocytosis and microgliosis, preserved neurons, and lessened memory decline. Biochemical and histological analyses showed that B28 engaged both plaque-bound and diffusible Aβ, forming immune complexes and depleting free Aβ. In in vitro immunoassays, B28 had significantly higher affinity and captured more Aβ from AD brain extracts than did lecanemab. B28 is a potent, aggregate-preferring Aβ antibody that clears plaques and decreases gliosis, supporting its clinical development.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: